VK2735 Isn't Just 'Another GLP-1' — The VENTURE Study Data Tells a Different Story
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
VK2735 Isn't Just 'Another GLP-1' — The VENTURE Study Data Tells a Different Story
The prevailing take on VK2735 is basically this: cool, another GIP/GLP-1 dual agonist, probably similar to tirzepatide, we'll wait and see.
That framing is understandable. But after reading through the Phase 2 VENTURE study data, I think it undersells what this compound actually demonstrated — and more importantly, it ignores a few numbers that don't fit the "tirzepatide clone" narrative at all.
Key Takeaways (TL;DR)
- VK2735 is a novel GIP/GLP-1 dual agonist studied in the Phase 2, randomized VENTURE trial published March 2026
- In just 13 weeks, participants on the highest dose saw weight reductions that rival or exceed what some competitors show at 17–20 weeks
- The speed-to-efficacy profile is the contrarian signal here — most coverage misses it
- VK2735 is not FDA-approved and is currently a research compound; this is an analysis of published trial data, not a treatment recommendation
- Important: I'm not a doctor. Everything here is based on published research and editorial analysis. Talk to your physician before making any changes to your health regimen.
What Everyone Is Saying About VK2735 (And Why It's Incomplete)
The standard coverage goes something like this: GLP-1 market is crowded, tirzepatide already does dual GIP/GLP-1, VK2735 is from Viking Therapeutics, another entrant, interesting but not revolutionary.
That's not wrong. It's just lazy.
The VENTURE study was a Phase 2, randomized, 13-week trial evaluating multiple doses of subcutaneous VK2735 in adults with obesity or overweight. Published in Obesity (Silver Spring) by Bays, Toth, Alkhouri et al. in March 2026. [1]
When you actually read the data — not the press summary, the data — the story changes.
The Number Everyone Is Glossing Over: 13 Weeks
Here's the contrarian take: the timeline is the headline, and almost no one is writing about it.
Most weight loss drug trials that generate excitement are measuring outcomes at 68 weeks (semaglutide's STEP trials), 72 weeks (tirzepatide's SURMOUNT trials), or longer. Impressive numbers over those timeframes are expected. The compounds had time to work.
VENTURE ran for 13 weeks.
That's three months and one week. What the highest-dose VK2735 group showed in that window was weight reduction that, on a per-week-of-treatment basis, warrants serious attention. The trial demonstrated statistically significant, dose-dependent reductions in body weight across multiple dose arms compared to placebo.
To be precise about what the published research shows — without overstating it — the higher-dose groups demonstrated mean placebo-adjusted weight loss in the range of roughly 13–14% body weight at 13 weeks in the top dose cohort, according to data from the VENTURE publication. [1]
For context: tirzepatide's SURMOUNT-1 trial showed ~15% weight reduction, but at 40 weeks into a 72-week study. [2]
That is not an apples-to-apples comparison. Different populations, different designs, different follow-up structures. But it is a meaningful data point that the "just another GLP-1" framing completely misses.
What VK2735 Actually Is (The Mechanism Matters Here)
Note: VK2735 is classified as a research compound and is not FDA-approved for human use. The information below is based on published Phase 2 clinical trial data. This is not a recommendation to use this compound. Consult a qualified healthcare provider.
VK2735 is a dual agonist targeting both the GLP-1 receptor and the GIP receptor — the same dual-target approach that makes tirzepatide (Mounjaro/Zepbound) distinct from earlier single-agonist GLP-1 drugs like semaglutide. [3]
The GLP-1 receptor piece is the more well-understood side: it slows gastric emptying, supports satiety signaling, and has downstream effects on glucose regulation. The GIP receptor piece is where research is still catching up. There's evidence the GIP agonism works synergistically with GLP-1 to amplify weight reduction and may help with tolerability. [4]
What makes VK2735 molecularly distinct from tirzepatide is its specific receptor binding profile and molecular structure — Viking Therapeutics has described it as optimized for dual agonism with a differentiated pharmacokinetic profile. The VENTURE data is the first Phase 2 look at whether that translates into human outcomes.
It does.
The Dose-Response Signal: More Interesting Than It Looks
VENTURE was designed as a dose-finding trial, which means the researchers tested several dose levels to understand the relationship between dose and effect. That structure gives us something valuable: a dose-response curve.
What the VENTURE data shows is a clear, statistically significant dose-dependent pattern. Higher doses produced greater weight reduction, which is what you want to see — it suggests the effect is real and mechanistically driven, not noise.
The lower dose arms still showed meaningful separation from placebo. This matters for a practical reason: it suggests there may be a therapeutic window where meaningful efficacy is achievable at doses that might carry a more manageable side effect burden.
Speaking of which...
Side Effects: The Data Doesn't Let VK2735 Off the Hook
Contrarian takes get credibility by not cherry-picking. So here's the honest read on tolerability from VENTURE.
The side effect profile is consistent with the GLP-1 class: nausea, vomiting, diarrhea, and constipation were the most commonly reported adverse events. This is not a surprise — it's the GLP-1 tax. Almost every compound in this class carries it to some degree. [1]
The higher dose arms showed higher rates of GI side effects, which is also the expected dose-response pattern for this class. Whether VK2735's specific profile is meaningfully better or worse than tirzepatide at comparable efficacy doses is something Phase 3 will need to answer — VENTURE wasn't powered or designed to make that comparison.
A recent expert consensus statement on GLP-1-based therapies highlighted that "dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence" are real limiting factors for the whole class — not just individual compounds. [5] VK2735 is not exempt from that reality.
What VENTURE does not tell us:
- Long-term cardiovascular outcomes
- Weight regain after discontinuation
- Safety beyond 13 weeks
- Comparative tolerability vs. tirzepatide in a head-to-head design
Anyone presenting this as a fully validated, ready-to-use compound is getting ahead of the data. It's not. Phase 3 is what this needs next.
Why the "Crowded Market" Framing Misses the Strategic Picture
The other thing mainstream coverage gets wrong is the market framing. "GLP-1 space is crowded, late entrants will struggle" — that's the conventional wisdom.
Here's the counterargument: the addressable population for effective obesity pharmacotherapy is enormous, global, and still dramatically undertreated. Even semaglutide and tirzepatide combined reach a fraction of the clinically eligible population, largely due to cost, supply, and tolerability barriers. [6]
A compound that shows comparable or superior short-term efficacy with a potentially differentiated tolerability or dosing profile doesn't need to "beat" tirzepatide. It needs to serve patients who can't access, afford, or tolerate existing options.
VENTURE doesn't prove VK2735 does that. But it does prove the compound works at the Phase 2 level — and that's the first gate every drug has to clear.
How VK2735 Fits Into the Broader Research Landscape
For anyone tracking the evolution of metabolic peptide research, VK2735 fits into a broader pattern worth understanding.
The field is moving from single-target to multi-target receptor agonism. GLP-1 alone → GLP-1 + GIP (tirzepatide, VK2735) → GLP-1 + GIP + glucagon (retatrutide, currently in Phase 3). Each additional receptor adds complexity, but potentially adds efficacy for different metabolic outcomes. [7]
VK2735 sits in the dual-agonist tier alongside tirzepatide but with a different molecular identity. Whether that difference translates into clinically meaningful differentiation — better tolerability at equivalent efficacy, faster onset, different off-target effects — is what Phase 3 needs to establish.
The oral formulation of VK2735 is also in development (Viking announced Phase 2 data on the oral version separately from VENTURE). The appetite suppression and weight loss research pipeline is clearly moving toward convenience as a competitive axis — the success of oral semaglutide and emerging oral GLP-1 candidates like orforglipron underscores this. [8]
VK2735 vs. Tirzepatide: How They Compare
Since both compounds target the same two receptors (GLP-1 and GIP), the comparison is inevitable. Here is a framework based on what the data currently supports.
Head-to-Head Comparison
| Factor | VK2735 (VENTURE Phase 2) | Tirzepatide (SURMOUNT-1 Phase 3) |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GIP + GLP-1 dual agonist |
| Developer | Viking Therapeutics | Eli Lilly |
| Trial phase | Phase 2 | Phase 3 (FDA approved) |
| Duration | 13 weeks | 72 weeks |
| Weight loss signal | ~13-14% at highest dose (13 wks) | ~22.5% at highest dose (72 wks) |
| Side effect profile | GI class effects (nausea, vomiting) | GI class effects (nausea, vomiting) |
| Oral formulation | In development (separate trial) | Not available |
| FDA approval | Not approved | Approved (Mounjaro/Zepbound) |
| Head-to-head data | Not available | Not available |
The Decision Framework
If you need something right now with a long track record: Tirzepatide is the clear choice. It is approved, prescribed, and has real-world data from millions of patients.
If you are watching the pipeline for what is next, especially oral formulations: VK2735 deserves serious attention. Viking Therapeutics is developing an oral tablet formulation alongside the injectable. An oral dual GIP/GLP-1 agonist, if efficacy data is confirmed, would represent a meaningful option for people who prefer or require oral administration.
If you are a researcher or clinician tracking the pipeline: The VENTURE dose-response relationship is clean, early efficacy is strong, and Viking has been executing their trial program efficiently. This is a legitimate competitor to watch.
If you are considering using an unregulated research version of VK2735: Do not. There is no meaningful safety or purity data outside of the clinical trial. The risk profile is genuinely unknown.
Why the Oral Formulation Changes the Conversation
One of the persistent access problems with GLP-1-class drugs is the injection barrier. Not everyone wants to self-inject weekly. An oral GLP-1/GIP dual agonist that matches injectable efficacy would be a genuinely different product. Orforglipron, a non-peptide oral GLP-1 receptor agonist, just published Phase 3 data showing non-inferiority to oral semaglutide. The oral GLP-1 space is moving fast.
What This Means If You're Paying Attention to the Research Space
For people who follow peptide and metabolic research closely, here's the practical takeaway from VENTURE:
VK2735 is a compound to watch, not a compound to use. It has cleared Phase 2. It has a legitimate, peer-reviewed efficacy signal. It has a named target (dual GIP/GLP-1), a mechanistic rationale, and a publication trail now.
What it doesn't have: FDA approval, long-term safety data, or a Phase 3 completion.
The research nerds reading this who are interested in what comes after tirzepatide — this is one of the candidates. Follow the Phase 3 enrollment. Watch for cardiovascular outcome trial design. Look for whether Viking pursues a head-to-head vs. tirzepatide in any arm of their trials.
That's when the real story gets written.
For related reading, check out our analysis of retatrutide's Phase 2 data, our breakdown of retatrutide vs. tirzepatide, and our deep dive on GLP-1 and energy expenditure.
FAQ: VK2735 and the VENTURE Study
Q: What is VK2735? VK2735 is a novel GIP/GLP-1 dual receptor agonist developed by Viking Therapeutics. It is currently a research compound being studied for potential weight management applications. It is not FDA-approved for human use.
Q: What did the VENTURE study find? The Phase 2 VENTURE study found that weekly subcutaneous VK2735 produced statistically significant, dose-dependent weight reduction over 13 weeks in adults with obesity or overweight, compared to placebo. The highest dose cohort showed substantial weight loss within the 13-week timeframe. Full results are published in Obesity (Silver Spring) by Bays et al., 2026.
Q: How does VK2735 compare to tirzepatide? Both are GIP/GLP-1 dual agonists. They share a target mechanism but are distinct molecular compounds. The VENTURE study was not designed as a head-to-head comparison with tirzepatide. A direct comparative trial would be needed to make efficacy or tolerability claims.
Q: What are the side effects of VK2735? In the VENTURE study, the most commonly reported adverse events were GI-related: nausea, vomiting, diarrhea, and constipation — consistent with the GLP-1 drug class. Higher doses showed higher rates of these effects. Long-term safety data does not yet exist.
Q: When will VK2735 be available? VK2735 is still in clinical development as of early 2026. Phase 3 trials would be required before any potential FDA approval process. There is no confirmed timeline for commercial availability.
Conclusion: Read the Study, Not Just the Headlines
The popular take on VK2735 is that it's a late entrant in a crowded space — interesting but probably not transformative.
The VENTURE data suggests that's the wrong frame. What a 13-week Phase 2 study actually showed is a compound producing meaningful, dose-dependent weight reduction at a speed that, per week of treatment, deserves to be taken seriously rather than filed under "more of the same."
That's not a claim that VK2735 is better than existing approved therapies. It's a claim that the data warrants more than a dismissive shrug.
The next move for anyone tracking this space: look for Phase 3 trial registration on ClinicalTrials.gov for VK2735, and watch whether Viking publishes longer-duration follow-up on the VENTURE cohort.
The headline won't be written until Phase 3. But Phase 2 just told us this one is worth reading.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.
Sources
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study — Bays HE, Toth P, Alkhouri N et al. Obesity (Silver Spring), 2026 Mar
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al. New England Journal of Medicine, 2022
Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist — SURMOUNT-1 trial reference
GIP and GLP-1 receptor dual agonism: synergistic mechanisms for metabolic benefit — Source: PubMed
Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement — Sievenpiper JL, Ard J, Blüher M et al. Obesity Pillars, 2026 Mar
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus — Angelopoulos N et al. International Journal of Obesity, 2026 Mar
[Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.